Stock Analiz

Outlook Therapeutics, Inc. OTLK

Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2016 · data as of November 13, 2026

$0.41Market cap $101M
Open the interactive analysis →

Outlook Therapeutics, Inc. (OTLK) is a healthcare company listed in the US with a market value of about $101M. In fiscal year 2025 it had revenue of $1M and net income of -$62M, a net margin of -4416.2%.

Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is future growth (1/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -232%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 100% below the current price.

About Outlook Therapeutics

Outlook Therapeutics is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2016. Revenue went from $5M in 2015 to $1M in 2025, a decline of about 12.2% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 228% over three years (dilution for shareholders). It spends 1923% of revenue on research and development.

Score: 0.6 / 5

Value0/5
Future growth1/5
Track record1/5
Financial health1/5
Shareholder returns0/5

Checks passed

  • Strong R&D investment or growth above 20%
  • ROE above 15%
  • More cash than debt, or low debt to equity

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S71.1
P/B—
EV/EBITDA—
PEG—
Dividend yield—
FCF yield—
Shareholder yield0.0%
Intrinsic value vs. price−100%

Growth and quality

Revenue growth (1 yr)—
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-4416.2%
ROIC (5-yr avg.)-232.3%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 10 years

Fiscal year2025202420232022202120202019201820172016
Revenue$1M—————$8M$3M$4M$3M
Net income-$62M-$75M-$59M-$66M-$53M-$35M-$35M-$30M-$39M-$53M
Free cash flow——————-$33M-$36M-$16M-$47M
EPS (diluted)$-1.79$-4.06$-4.72$-6.20$-7.00$-13.40$-39.60$-24.40$-36.00$-73.40
Net margin-4416.2%—————-423.8%-974.6%-1019.3%-1788.9%
ROIC——-198.8%-250.7%-247.4%-849.5%————

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Is Outlook Therapeutics stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 100% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Outlook Therapeutics pay a dividend?

Not currently.

Is Outlook Therapeutics a good stock to buy?

We do not give buy or sell advice. Outlook Therapeutics scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.